Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1093/ofid/ofaa241 http://scihub22266oqcxt.onion/10.1093/ofid/ofaa241 C7337805!7337805!32671131     free     free     free Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Open+Forum+Infect+Dis 2020 ; 7 (7): ä Nephropedia Template TP {{tp|p=32671131|t=2020. Antiviral Activity and Safety of Darunavir/Cobicistat for the Treatment of COVID-19 |pdf=|usr=}}{{32671131}} gab.com Text Antiviral Activity and Safety of Darunavir/Cobicistat for the Treatment of COVID-19 JO: Open Forum Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=32671131 #FOAvip Background: We aimed to evaluate the antiviral activity and safety of darunavir/cobicistat (DRV/c) in treating COVID-19 patients. Methods: In this single-center, randomized, and open-label trial, mild patients with polymerase chain reaction (PCR)?confirmed COVID-19 were enrolled in Shanghai, China. Participants were randomized to receive DRV/c for 5 days on the top of interferon alpha 2b inhaling or interferon alpha 2b inhaling alone. The primary end point was the virological clearance rate of oropharyngeal swabs at day 7 after randomization in the intention-to-treat population (clinicaltrials.gov: NCT04252274). Results: From January 30, 2020, to February 6, 2020, a total of 30 patients were enrolled, of whom 18 (60%) were male, aged 47.2?±?2.8 years; 63.3% (19/30) of the participants had fever, and 46.7% (14/30) had cough at enrollment. The participants were randomized (range) at 4 (2?5) days after onset of symptoms. The proportion of negative PCR results at day 7 was 46.7% (7/15) and 60.0% (9/15) in the DRV/c and control groups (P?=?.72), respectively. The viral clearance rate at day 3 was 20% (3/15) in both study groups, while the number increased to 26.7% (4/15) in the DRV/c group and remained 20% (3/15) in the control group at day 5. Fourteen days after randomization, 1 participant in the DRV/c group progressed to critical illness and discontinued DRV/c, while all the patients in the control group were stable (P?=?1.0). The frequencies of adverse events in the 2 groups were comparable. Conclusions: Five days of DRV/c did not increase the proportion of negative conversion vs standard of care alone, although it was well tolerated. Twit Text FOAVip Antiviral Activity and Safety of Darunavir/Cobicistat for the Treatment of COVID-19 ????Open Forum Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=32671131 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32671131 #FOAvip English Wikipedia <ref>{{Cite pmid|32671131}}</ref> Antiviral Activity and Safety of Darunavir/Cobicistat for the Treatment of COVID-19 #MMPMID32671131 Chen J; Xia L; Liu L; Xu Q; Ling Y; Huang D; Huang W; Song S; Xu S; Shen Y; Lu H Open Forum Infect Dis 2020[Jul]; 7 (7): ä PMID32671131show ga Background: We aimed to evaluate the antiviral activity and safety of darunavir/cobicistat (DRV/c) in treating COVID-19 patients. Methods: In this single-center, randomized, and open-label trial, mild patients with polymerase chain reaction (PCR)?confirmed COVID-19 were enrolled in Shanghai, China. Participants were randomized to receive DRV/c for 5 days on the top of interferon alpha 2b inhaling or interferon alpha 2b inhaling alone. The primary end point was the virological clearance rate of oropharyngeal swabs at day 7 after randomization in the intention-to-treat population (clinicaltrials.gov: NCT04252274). Results: From January 30, 2020, to February 6, 2020, a total of 30 patients were enrolled, of whom 18 (60%) were male, aged 47.2?±?2.8 years; 63.3% (19/30) of the participants had fever, and 46.7% (14/30) had cough at enrollment. The participants were randomized (range) at 4 (2?5) days after onset of symptoms. The proportion of negative PCR results at day 7 was 46.7% (7/15) and 60.0% (9/15) in the DRV/c and control groups (P?=?.72), respectively. The viral clearance rate at day 3 was 20% (3/15) in both study groups, while the number increased to 26.7% (4/15) in the DRV/c group and remained 20% (3/15) in the control group at day 5. Fourteen days after randomization, 1 participant in the DRV/c group progressed to critical illness and discontinued DRV/c, while all the patients in the control group were stable (P?=?1.0). The frequencies of adverse events in the 2 groups were comparable. Conclusions: Five days of DRV/c did not increase the proportion of negative conversion vs standard of care alone, although it was well tolerated. äAntiviral Activity and Safety of Darunavir/Cobicistat for the Treatmen(epmc).pdf DeepDyve Pubget Overpricing